BACKGROUND

The aesthetic use of hyaluronic acid (HA) has led to the development of various commercial HA fillers. Crosslinked HA dermal fillers are commonly used to treat facial wrinkles. This study demonstrated the non-inferiority of the newly developed hyaluronic acid filler by comparing its efficacy and safety to that of the existing hyaluronic acid filler.

METHODS

This 48-week study was designed as a randomized, double-blind, split-face trial. Subjects who met the inclusion and exclusion criteria had a total of four follow-up visits after receiving a dermal filler in the nasolabial folds. Efficacy was assessed using the Wrinkle Severity Rating Score (WSRS) and the Global Aesthetic Improvement Scale (GAIS). Safety was determined through the evaluation of laboratory tests, monitoring adverse events, and verifying vital signs.

RESULTS

WSRS measured at week 24 of the follow-up visit showed no statistically significant difference, with scores of 2.02 ± 0.71 in the new filler group and 2.27 ± 0.68 in the existing filler group. Even at the 48-week follow-up visit, the improvement rate in the Wrinkle Severity Rating Scale (WSRS) of more than 1 point did not show a statistically significant difference between the new filler group and the existing filler group. The GAIS scores at each follow-up visit showed no statistically significant differences between the two groups. The most frequently reported symptoms related to the test device during the 48-week trial were pain and swelling. However, these symptoms were not statistically significant when compared to the control group from a treatment perspective.

CONCLUSIONS

In a 48-week clinical trial aimed at treating nasolabial fold (NLF) wrinkles, the new hyaluronic acid (HA) filler demonstrated efficacy and safety comparable to that of existing control filler. As a result, the new HA filler is both an effective and safe option for improving NLF wrinkles.

TRIAL REGISTRATION

This study was registered with ClinicalTrials.gov under the registration number NCT06310863.